Optimization of acyclovir oral tablets based on gastroretention technology: Factorial design analysis and physicochemical characterization studies

Drug Development and Industrial Pharmacy

Volumn 37, Issue 7, 2011, Pages 855-867

  El Gamal, Safaa S ^a   Naggar, Viviane F ^a   Allam, Ahmed N ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Acyclovir; bioavailability; Compritol; factorial design; floating time; gastroretentive; HPMC

Indexed keywords

ACICLOVIR; BICARBONATE; GLYCEROL BEHENATE; HYDROXYPROPYLMETHYLCELLULOSE;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; CORRELATION ANALYSIS; DATA ANALYSIS SOFTWARE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RETENTION; DRUG STORAGE; FACTORIAL DESIGN; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHYSICAL CHEMISTRY; PREDICTIVE VALUE; TABLET; TABLET COMPRESSION;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; METHYLCELLULOSE; PHYSICOCHEMICAL PHENOMENA; SODIUM BICARBONATE; STOMACH; TABLETS;

EID: 79958708031     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.546404     Document Type: Article

References (44)

1. Barakat NS, Elbagory IM, Almurshedi AS. (2009). Controlled-release carbamazepine matrix granules and tablets comprising lipophilic and hydrophilic components. Drug Deliv, 16:57-65
2. Barhate SD, Patel KM, Rupnar YS. (2009). Formulation optimization of controlled release floating tablets of amoxacillin trihydrate with K-clavulanate. J Pharmacy Res, 2:1471-1474
3. Boldhane SB, Kuchekar BS. (2009). Gastroretentive drug delivery system of quetiapine fumarate: formulation and in vitro evaluation using 32 full factorial design. J Pharm Res, 2:1429-1433
4. Brijesh SD, Avani FA. (2004). Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS Pharmscitech, 5:34-39
5. Chawla G, Bansal A. (2003). A means to address regional variability in intestinal drug absorption. Pharm Technol, 27:50-68
6. Chengsheng L, Kashappa G, Xuexi T, Xiguang C. (2006). Drug release kinetics of spray-dried chitosan microspheres. Drying Technol, 24:769-776
7. Dasharath MP, Natavarlal MP, Viral FP, Darshini AB. (2007). Floating granules of ranitidine hydrochloride-gelucire 43/01: formulation optimization using factorial design. AAPS Pharmscitech 8:1-8
8. Deshpande AA, Rhodes CT, Shah NH. (1996). Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm, 22:531-539 (Pubitemid 26197851)
9. Deshpande AA, Shah NH, Rhodes CT, Malick W. (1997). Development of a novel controlled-release system for gastric retention. Pharm Res, 14:815-819 (Pubitemid 27281680)
10. Design Expert, Stat-Ease Inc. (2008). (http://www.statease.com/ dx8descr.html). Minneapolis, USA
11. Dhaliwal S, Jain S, Singh HP, Tiwary AK. (2008). Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J, 10:322-330
12. Fukuda M, Peppas NA, McGinity JW. (2006). Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J Control Release, 115:121-129 (Pubitemid 44537498)
13. Gambhire MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR. (2007). Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS Pharmscitech, 8:E73
14. Garg R, Gupta GD. (2009). Preparation and evaluation of gastroretentive floating tablets of Silymarin. Chem Pharm Bull, 57:545-549
15. Gennaro AR. (2005). Antivirals. In: Remington PJ (ed.), Remingtonás Pharmaceutical Sciences. Mack: Easton, PA, pp. 1675-1677
16. Gibaldi M, Feldman S. (1967). Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci, 56:1238-1242
17. Gromova LI, Hoichman D, Sela J. (2007). Gastroretentetivesustained release acyclovir tablets based on synergistically interacting polysaccharides. Pharma Chem J, 41:656-659
18. Gutiérrez-Sánchez PE, Hernández-León A, Villafuerte-Robles L. (2008). Effect of sodium bicarbonate on the properties of metronidazole floating matrix tablets. Drug Dev Ind Pharm, 34:171-180 (Pubitemid 351317146)
19. Higuchi T. (1961). Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci, 50:874-875
20. Higuchi T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52:1145-1149
21. Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. (2004). Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release, 100:331-346 (Pubitemid 39572916)
22. Junyaprasert VB, Pornsuwannapha S. (2008). Floating properties and release characteristics of hollow microspheres of acyclovir. Drug Deliv, 15:331-341
23. Kiortsis S, Kachrimanis K, Broussali T, Malamataris S. (2005). Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component. Eur J Pharm Biopharm, 59:73-83 (Pubitemid 39573439)
24. Kopcha M, Lordi NG, Tojo KJ. (1991). Evaluation of release from selected thermosoftening vehicles. J Pharm Pharmacol, 43:382-387
25. Li FQ, Hu JH, Deng JX, Su H, Xu S, Liu JY. (2006). In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int J Pharm, 324:152-157 (Pubitemid 44528916)
26. Lund W. (1994). Pharmaceutical Codex. Pharmaceutical Press: London, pp. 711-713
27. Mayur GS, Rajashree CM, Jolly MS. (2007). Reversed chitosan-alginate polyelectrolyte complex for stability improvement of amylase: optimization and physicochemical characterization. Eur J Pharm Biopharm, 65:215-232
28. Menon A, Ritschel WA, Sakr A. (1994). Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci, 83:239-245 (Pubitemid 24224185)
29. Monica RR, Girish SS, Rachana RM, Swapnila DV. (2009). Evaluation of effervescent floating matrix tablet formulations of salbutamol sulfate using full factorial design. Asian J Pharm, 3: 43-49
30. Patel A, Modasiya M, Shah D, Patel V. (2009). Development and in vivo floating behavior of verapamil HCl intragastric floating tablets. AAPS Pharmscitech, 10:310-315
31. Patel DM, Patel NM, Pandya NN, Jogani PD. (2007). Formulation and optimization of carbamazepine floating tablets. Ind J Pharm Sci, 69:763-767
32. Ritger PL, Peppas NA. (1987). A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Rel, 5:37-42 (Pubitemid 17106644)
33. Santus G, Lazzarini G, Bottoni G. (1997). An in vitro-in vivo investigation of oral bioadhesive controlled release furosemide formulations. Eur J Pharm Biopharm, 44:39-52 (Pubitemid 28298774)
34. Sasa BA, Julijana KA, Franc V, Polona V. (2000). Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm 195:125-135
35. Siepmann J, Peppas NA. (2001). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev, 48:139-157 (Pubitemid 32434400)
36. Singh BN, Kim KH. (2000). Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 63:235-259
37. Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. (2005). Oral sustained delivery of atenolol from floating matrix tabletsformulation and in vitro evaluation. Drug Dev Ind Pharm, 31: 367-374 (Pubitemid 41289149)
38. Strübing S, Metz H, Mäder K. (2008). Characterization of poly(vinyl acetate) based floating matrix tablets. J Control Release, 126:149-155
39. Stulzer HK, Tagliari MP, Parize AL,Silva MA. (2009). Evaluation of cross-linked chitosan microparticles containing acyclovir obtained by spray-drying. Materials Sci Eng, 29:387-392
40. Sungthongjeen S, Sriamornsak P, Puttipipatkhachorn S. (2008). Design and evaluation of floating multi-layer coated tablets based on gas formation. Eur J Pharm Biopharm, 69:255-263 (Pubitemid 351467157)
41. Tadros MI. (2010). Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. Eur J Pharm Biopharm, 74:332-339
42. Wagner JG. (1969). Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci, 58:1253-1257
43. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith A. (1998). Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release, 55:3-12 (Pubitemid 28477559)
44. Zhao L, Yang X, Xu R, Wu J, Gu S, Zhang L et al. (2009). Safety, tolerability and pharmacokinetics of phenoprolamine hydrochloride floating sustained-release tablets in healthy Chinese subjects. Int J Pharm, 377:99-104